Research and Markets - The Antihypertensive Market Accounted for Almost $30 Billion In the Seven Major Markets in 2003 and This Value Is Set To Rise as Prevalence Increases

Research and Markets (researchandmarkets.com/reports/c10451) has announced the addition of Commercial Insight: Antihypertensives - Can Manufacturers Maintain Value? to their offering.

(PRWEB) December 8, 2004 -- The increasing use of multiple drug therapy and the falling use of older drug classes in the absence of specific compelling indications is continuing to drive sales of the largest classes and will provide a growing market for an new entrants.

Research and Markets (http://www.researchandmarkets.com/reports/c10451) has announced the addition of Commercial Insight: Antihypertensives - Can Manufacturers Maintain Value? to their offering.

The scope of this report is as follows:
- Country specific event-driven sales forecasts for the period 2004-14 for the US, Japan, France, Germany, Italy, Spain and the UK and Global overview
- Patient potential and prescribing trends overview of the antihypertensive market based on historical sales data and future key events
- Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and class switching
- Case studies presenting the effect of launch strategy into the ARB market, additional indications and outcome-based clinical trials

The highlights of this report are as follows:
- The antihypertensive market has seen continuing growth driven by increasing global prevalence and more aggressive treatment allow it to grow to a 30 billion dollar market in 2003, these trends are set to continue but as governments seek to reduce healthcare spending antihypertensives will come under scrutiny as a source of savings.

- Patent expiries of major brands will be the leading events shaping the future of the antihypertensives market in the period until 2014, the global market leader, Norvasc, and the fastest growing class, ARBs, will both face genericization during this period, driving down costs and encouraging switching from older classes.

- This report forecasts that combination products will drive sales in the ARB class once key product patent expiries force allow genericization of plain formulation products, however physicians are often cynical of manufacturers motives for producing these combinations and the benefits to patients must be highlighted to maintain physician confidence.

Reasons to Purchase are as follows:
- Identify possible future strategy to maximize product potential and minimize risks for the ARB market
- View independent, event-driven forecasts for key antihypertensive products and classes across the seven major markets
- Assess the impact of the Norvasc patent expiry on the market and identify which CCBs, if any, could benefit from the increased competition

The contents of this report are as follows
Chapter 1 Executive Summary
Chapter 2 Current Market Assessments
Chapter 3 Forecast Analysis
Chapter 4 Commercial Impact And Lifecycle Management: Case Studies
Appendix A -- Market Data And Major Brand Key Facts

For more information visit http://www.researchandmarkets.com/reports/c10451

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980

###